Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00340223

HLA-B35 Alleles and AIDS

Comparison of HIV-1 Epitopes That May be Recognized by HLA-B*3501 (PY) and -B*3503 (Px) Early After Seroconversion and After Development of AIDS

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
National Cancer Institute (NCI) · NIH
Sex
All
Age
21 Years
Healthy volunteers
Accepted

Summary

This study will identify variations in the genome of the human immunodeficiency virus (HIV) early after infection and following the development of AIDS. It will analyze genetic material and clinical data from HIV-positive individuals to assess differences in viral epitopes between patients with two different gene alleles (alternative forms of a gene)-B\*3501 and B\*3503. (An epitope is a molecular region on the surface of an antigen capable of eliciting an immune response and of combining with the specific antibody produced by such a response.) HIV disease in people with the B\*3503 allele progresses significantly faster than it does in people with the B\*3501 allele. This study might provide information that is potentially useful in developing a successful HIV vaccine. Blood samples and clinical data for analysis will be obtained from the Johns Hopkins Bloomberg School of Public Health; the University of Pittsburgh; the John H. Stroger, Jr. Hospital of Cook County; the Howard Brown Health Center; Northwestern University; and the University of California at Los Angeles.

Detailed description

The purpose of this study is to identify variations in the genome of HIV early after infection and following the development of AIDS to determine the location of escape mutations that might provide information about potential B\*35 epitopes. These data will be useful in explaining the difference in disease progression between individuals possessing B\*35 Px alleles and those with B\*35 PY alleles. We have previously shown that individuals with B\*35 Px alleles progress at a significantly faster rate compared to those with B\*35 PY alleles. This study might provide information which is potentially useful in the development of a successful HIV vaccine.

Conditions

Timeline

Start date
2005-09-01
Completion
2007-09-01
First posted
2006-06-21
Last updated
2012-05-10

Locations

7 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00340223. Inclusion in this directory is not an endorsement.